RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail aims to tame Hard-to-Treat lymphoma
Disease control TerminatedThis early-phase trial tests whether adding the drug tazemetostat to two standard lymphoma drugs (zanubrutinib and an anti-CD20 antibody) is safe and works for people with indolent B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 24 adults …
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New CAR-T therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new treatment called JNJ-90009530 for adults with B-cell Non-Hodgkin lymphoma that has come back or not responded to other therapies. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals are to find a safe dose and se…
Matched conditions: RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 08:32 UTC